AMR’s stellar performance in vaccine trials has earned the company a reputation of excellence across the industry.
In 2020, during the global Coronavirus pandemic, one AMR clinical research center – AMR Kansas City – was selected as one of the two first centers in the nation to conduct a COVID-19 Investigational Vaccine Clinical Research Study. Since then, AMR has worked tirelessly to obtain COVID-19 studies including vaccinations, diagnosis and treatment.
AMR is a three-time recipient of the World Vaccine Congress’s Vaccine Industry Excellence (ViE) Award for “Best Clinical Trial Site or Network” (2013, 2015, 2017) and was a finalist for this prestigious award in 2016 and 2018.
Average Enrollment Goal Achieved
Average Retention Rate
Biopharma & Government Clients
Phase I Trials
2,500 subjects enrolled in 60+ Phase I studies
117% average enrollment goal for phase I trials
90% average retention rate for phase I trials
22 Phase I vaccine indications
26 Phase I biopharma and government agency
Private practice access for patient-flow and database mining
Adjacency and partnerships with leading medical facilities in each market
Regularly scheduled community outreach and education program
Customized local media campaigns
Experienced Support Staff
Blinded and unblinded support staff personnel
Dedicated patient recruiters
Media, PR and marketing specialists
Data & QA managers
Licensed pharmacy technicians and trained pharmacists
Industry Leading Capabilities
Local PBMC processing
Live-attenuated vaccine handling
Biosafety Level II cabinets
Biosafety Level I & II certifications
Sterile drug preparation environments
Federal Wide Assurance (FWA) numbers
Established local Institutional Biosafety Committees (IBC)
AMR locations nationwide are currently seeking adults ages 18 and over for multiple Healthy Volunteer clinical research studies. AMR research centers are also enrolling in multiple COVID-19 investigational studies.